AIMS/HYPOTHESIS: A reduction in the number of endothelial progenitor cells (EPCs) is considered a plausible cause of increased cardiovascular risk in diabetes mellitus. The aim of this study was to test the hypothesis that weak bone marrow mobilisation is responsible for the decrease in circulating EPCs in diabetes. MATERIALS AND METHODS: We employed a model of hindlimb ischaemia-reperfusion (I/R) injury to study mobilisation of EPCs in control and streptozotocin diabetic rats. EPCs were defined by flow cytometry as Sca-1(+) and Sca-1(+)c-kit(+) peripheral blood cells and further characterised by the expression of CD31, von Willebrand factor and fetal liver kinase-1. Capillary density was evaluated by immunofluorescent staining of vWF. We also determined plasma levels of stromal cell-derived factor (SDF-1) and vascular endothelial growth factor (VEGF) by ELISA and muscle expression of hypoxia-induced factor (HIF-1alpha) by Western blotting. RESULTS: In control rats, EPCs showed a mobilisation curve within 7 days, while diabetic rats were completely unable to mobilise EPCs after I/R injury. As a consequence, diabetic rats showed no compensatory increase in muscle capillary density. Defective EPC mobilisation in diabetes was associated with altered release of SDF-1 and VEGF and inability to upregulate muscle HIF-1alpha. Both insulin administration and premedication with granulocyte-colony stimulating factor and stem cell factor led to partial recovery in post-ischaemic mobilisation of EPCs in diabetic rats. CONCLUSIONS/ INTERPRETATION: Defective ischaemia-induced bone marrow mobilisation of EPCs impedes compensatory angiogenesis in ischaemic tissues of diabetic animals. Growth factor administration together with blood glucose control may offer a rational therapeutic strategy for diabetic ischaemic syndromes.
AIMS/HYPOTHESIS: A reduction in the number of endothelial progenitor cells (EPCs) is considered a plausible cause of increased cardiovascular risk in diabetes mellitus. The aim of this study was to test the hypothesis that weak bone marrow mobilisation is responsible for the decrease in circulating EPCs in diabetes. MATERIALS AND METHODS: We employed a model of hindlimb ischaemia-reperfusion (I/R) injury to study mobilisation of EPCs in control and streptozotocindiabeticrats. EPCs were defined by flow cytometry as Sca-1(+) and Sca-1(+)c-kit(+) peripheral blood cells and further characterised by the expression of CD31, von Willebrand factor and fetal liver kinase-1. Capillary density was evaluated by immunofluorescent staining of vWF. We also determined plasma levels of stromal cell-derived factor (SDF-1) and vascular endothelial growth factor (VEGF) by ELISA and muscle expression of hypoxia-induced factor (HIF-1alpha) by Western blotting. RESULTS: In control rats, EPCs showed a mobilisation curve within 7 days, while diabeticrats were completely unable to mobilise EPCs after I/R injury. As a consequence, diabeticrats showed no compensatory increase in muscle capillary density. Defective EPC mobilisation in diabetes was associated with altered release of SDF-1 and VEGF and inability to upregulate muscle HIF-1alpha. Both insulin administration and premedication with granulocyte-colony stimulating factor and stem cell factor led to partial recovery in post-ischaemic mobilisation of EPCs in diabeticrats. CONCLUSIONS/ INTERPRETATION: Defective ischaemia-induced bone marrow mobilisation of EPCs impedes compensatory angiogenesis in ischaemic tissues of diabetic animals. Growth factor administration together with blood glucose control may offer a rational therapeutic strategy for diabetic ischaemic syndromes.
Authors: Alexis S Bailey; Shuguang Jiang; Michael Afentoulis; Christina I Baumann; David A Schroeder; Susan B Olson; Melissa H Wong; William H Fleming Journal: Blood Date: 2003-09-04 Impact factor: 22.113
Authors: S Gadau; C Emanueli; S Van Linthout; G Graiani; M Todaro; M Meloni; I Campesi; G Invernici; F Spillmann; K Ward; P Madeddu Journal: Diabetologia Date: 2006-01-17 Impact factor: 10.122
Authors: D Orlic; J Kajstura; S Chimenti; F Limana; I Jakoniuk; F Quaini; B Nadal-Ginard; D M Bodine; A Leri; P Anversa Journal: Proc Natl Acad Sci U S A Date: 2001-08-14 Impact factor: 11.205
Authors: Deling Kong; Luis G Melo; Massimiliano Gnecchi; Lunan Zhang; Gustavo Mostoslavsky; Chong C Liew; Richard E Pratt; Victor J Dzau Journal: Circulation Date: 2004-09-27 Impact factor: 29.690
Authors: Daniel J Ceradini; Anita R Kulkarni; Matthew J Callaghan; Oren M Tepper; Nicholas Bastidas; Mark E Kleinman; Jennifer M Capla; Robert D Galiano; Jamie P Levine; Geoffrey C Gurtner Journal: Nat Med Date: 2004-07-04 Impact factor: 53.440
Authors: Ulf Landmesser; Niels Engberding; Ferdinand H Bahlmann; Arnd Schaefer; Antje Wiencke; Andre Heineke; Stephan Spiekermann; Denise Hilfiker-Kleiner; Christian Templin; Daniel Kotlarz; Maja Mueller; Martin Fuchs; Burkhard Hornig; Hermann Haller; Helmut Drexler Journal: Circulation Date: 2004-10-05 Impact factor: 29.690
Authors: Sandip Sarkar; Thomas Schmitz-Rixen; George Hamilton; Alexander M Seifalian Journal: Med Biol Eng Comput Date: 2007-03-06 Impact factor: 2.602
Authors: G P Fadini; L Pucci; R Vanacore; I Baesso; G Penno; A Balbarini; R Di Stefano; R Miccoli; S de Kreutzenberg; A Coracina; A Tiengo; C Agostini; S Del Prato; A Avogaro Journal: Diabetologia Date: 2007-06-20 Impact factor: 10.122
Authors: Jinglian Yan; Guodong Tie; Brian Park; Yagai Yan; Philip T Nowicki; Louis M Messina Journal: J Vasc Surg Date: 2009-10-17 Impact factor: 4.268
Authors: C G Egan; R Lavery; F Caporali; C Fondelli; F Laghi-Pasini; F Dotta; V Sorrentino Journal: Diabetologia Date: 2008-02-20 Impact factor: 10.122